Medical Marijuana Investment AXIM® Biotech Announces Enrolled Patients Begin Phase II Trial For The Treatment Of Irritable Bowel Syndrome

Medical Marijuana, Inc. (OTC:MJNA) major investment company AXIM® Biotechnologies announced the enrolment of 40 patients and started its Phase II clinical trial for the treatment of irritable bowel syndrome (IBS) with the company’s CanChew Plus® CBD gum.
As quoted in the press release:

Selected from a pool of over 400 patients, 40 trial patients aged 18-65 will be subject to a randomized, double-blind, cross-over trial of 8 weeks. Patients will receive a maximum 6 chewing gums per day, either containing 50 mg of cannabidiol per chewing gum in case of the CanChew chewing gum, or a placebo chewing gum.
Final data collection for primary outcome measure is estimated to complete in April 2017, with the full study estimated to complete in June 2017.

Click here for the full press release.